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Abstract
Background: Understanding drivers for metastasis in human cancer is important for potential development of therapies to
treat metastases. The role of loss of TGFb tumor suppressor activities in the metastatic process is essentially unknown.
Methodology/Principal Findings: Utilizing in vitro and in vivo techniques, we have shown that loss of TGFb tumor
suppressor signaling is necessary to allow the last step of the metastatic process - colonization of the metastatic site. This
work demonstrates for the first time that TGFb receptor reconstitution leads to decreased metastatic colonization.
Moreover, we have identified a novel TGFb/PKA tumor suppressor pathway that acts directly on a known cell survival
mechanism that responds to stress with the survivin/XIAP dependent inhibition of caspases that effect apoptosis. The
linkage between the TGFb/PKA transduceome signaling and control of metastasis through induction of cell death was
shown by TGFb receptor restoration with reactivation of the TGFb/PKA pathway in receptor deficient metastatic colon
cancer cells leading to control of aberrant cell survival.
Conclusion/Significance: This work impacts our understanding of the possible mechanisms that are critical to the growth
and maintenance of metastases as well as understanding of a novel TGFb function as a metastatic suppressor. These results
raise the possibility that regeneration of attenuated TGFb signaling would be an effective target in the treatment of
metastasis. Our work indicates the clinical potential for developing anti-metastasis therapy based on inhibition of this very
important aberrant cell survival mechanism by the multifaceted TGFb/PKA transduceome induced pathway. Development
of effective treatments for metastatic disease is a pressing need since metastases are the major cause of death in solid
tumors.
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Introduction
Colorectal cancer (CRC) is one of the most common
malignancies with high incidence rates globally [1] and is the
second highest cause of cancer related death among adults in the
United States [2]. CRC can be cured by surgery and multimodal
treatment in about half of the individuals with this disease (Stages
I–III). However, metastasis to distant organs (Stage IV) is the most
frequent cause of treatment failure [2]. Recent work has stressed
on the importance of the development of inappropriate cell
survival signaling for various steps in the metastatic process.
Particularly noteworthy in the context of survival signaling in the
metastatic process is the importance of aberrant cell survival to
successful colonization at metastatic sites in distal organs [3].
Importantly, molecular mechanisms involved in the early stage of
metastasis critical for diagnosis and therapy are not well
understood [1]. Several key players including the Bcl-2, inhibi-
tor-of-apoptosis (IAP) proteins XIAP and survivin, and the
phosphoinositide 3-kinase (PI3K) – AKT/PKB which transmit
anti-apoptotic signals in promoting cancer cell growth have been
implicated in metastasis [4,5].
Tumor suppressor genes (TSG) contribute to the induction of
apoptosis in response to stress. The failure to induce apoptosis in
response to various types of cellular damage has been long
recognized as contributing to oncogenesis. One example of TSG
loss contributing to cancer formation and progression is TGFb
signaling [2]. The TGFb signaling pathway has been contributing
both negatively and positively in regulating growth inhibition,
proliferation, replication, invasion, metastasis, apoptosis, immune
surveillance and angiogenesis in a context dependent manner [6].
TGFb inhibitory/tumor suppressor responses are decreased with
increasing progression and in late stage malignancies are often
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While corruption of TGFb responses to support metastasis implies
the presence of functional receptors in these cells, it is equally clear
that there are substantial numbers of models ranging from
transgenic mice to human cancer xenografts indicating that loss,
or attenuation, of receptor expression in a wide variety of tumor
types leads to increased malignancy [7,8,9,10]. These results
suggest that some subgroups of cancers have pursued a pathway
toward malignant progression involving the loss of TGFb receptor
expression while others have, in a yet undetermined fashion,
usurped TGFb signaling to drive malignant progression. There are
several examples of TGFb receptor silencing in clinical samples
indicating that TGFb receptor RI and/or RII (designated
TGFbRI and TGFbRII respectively) downregulation are early
events in oncogenesis and that loss of receptor expression by
epigenetic silencing correlates to malignant progression in
subgroups of several types of cancer [11,12].
We have shown that TGFb signaling in an early stage non-
metastatic colon carcinoma model leads to cell death in colon
cancer cells in response to stress in association with inactivation of
pAKT and inhibition of the expression of the IAP protein survivin
[13]. Complex formation between survivin and another IAP
protein XIAP in the cytoplasm in response to stress enables
stabilization of XIAP and inhibition of its effector and executioner
caspase targets to inhibit cell death [14]. Therefore, given the
dominating role of PI3K/AKT signaling in cell survival
mechanisms and the association of XIAP and survivin in cancer
progression [5], we posited that loss of TGFb signaling may
contribute to enhanced XIAP/survivin expression and conse-
quently loss of TGFb signaling may be a key to an aberrant
survival mechanism permitting metastatic growth at distal organ
sites in contrast to the current view that TGFb TSG is primarily a
gatekeeper to prevent oncogenesis.
TGFb signaling has been shown to activate cAMP- dependent
Protein Kinase A (PKA) [15]. PKA plays a dominant role in the
integration of multiple signal transduction networks [16] including
the ability to disrupt the XIAP/survivin complex through
phosphorylation of survivin on Ser
20 [17].
The molecular mechanisms involved in the TGFb mediated
downregulation of IAP were investigated in order to determine the
effects of TGFb receptor signaling on metastasis in a metastatic
orthotopic model of colon carcinoma. We now report the
identification of a novel TGFb/PKA/AKAP mediated transdu-
ceome that converges on XIAP function in controlling aberrant
cell survival. Additionally, we have shown that TGFb receptor
rescue in highly metastatic cells with epigenetic silencing of TGFb
receptors leads to decreased metastases in a TGFb/PKA signaling
pathway dependent mechanism in a highly metastatic orthotopic
colon cancer models in vivo. Rescue of specific tumor suppressor
aspects of the TGFb signaling pathway may provide therapeutic
benefits without promoting the cell survival and metastatic effects
of TGFb. If these TGFb tumor suppressor effects can be mimicked
in late stage tumors, therapeutic value against metastatic CRC
might ultimately be obtained.
Results
TGFb activates PKA in colon cancer cells
A critical report from the Simeone laboratory noted that TGFb
signaling activates PKA in Mv1Lu cells and mediates control of
TGFb growth inhibitory responses [15]. TGFb activation of PKA
was mediated by a Smad-dependent, cyclic AMP (cAMP)-
independent mechanism. This raised the possibility that the
TGFb signaling mediated control of aberrant cell survival
observed in the early stage TGFb-sensitive FET colon carcinoma
model might involve the activation of PKA. We hypothesized that
TGFb activates PKA in FET cells in a cAMP independent, Smad
dependent mechanism. To this end, FET cells were treated with
TGFb (5 ng/ml) for specified times, and a protein kinase assay was
performed for measuring PKA activity (Figure 1A). Following
TGFb treatment, PKA activity increased by approximately 2-fold
within 15 min and 4-fold at 1 h. It was observed that TGFb
mediated PKA activation was completely abolished following
pretreatment of cells with H89 (15 mM), a pharmacological PKA
inhibitor [15]. TGFb mediated activation of PKA was also
concentration dependent (Figure 1B) with maximal activity in FET
cells observed at 5 ng/ml TGFb. To confirm that activation of
PKA was downstream of Smad activation by TGFb, we observed
that pretreatment with H89 had no effect on phosphorylation of
Smad2 by TGFb using immunoblot analysis (Figure S1). We
developed stable PKA catalytic a subunit shRNA knockdown in
FET cells (designated FET PKACata KD) to validate the H89
response genetically (Figure S2). TGFb treatment for the specified
times was unable to activate PKA in the knockdown cells as
opposed to robust activation in the parental FET cells (Figure 1C).
Activation of PKA by TGFb has been shown to be cAMP
independent in Mv1Lu cells [15]. Classical PKA activation
involves cAMP binding to the regulatory subunits of PKA to
trigger dissociation of the catalytic subunits. An alternative
mechanism of PKA activation involves the association of IkB
with PKA catalytic subunits, thereby maintaining an inactive state
of PKA. Upon IkB degradation, there is activation of PKA
independent of cAMP activation [18]. We determined whether
activation of PKA by TGFb is dependent upon cAMP activation
in FET cells by treating cells with TGFb and measuring cAMP
levels using a non-radioactive cAMP enzyme immunoassay
(Figure 1D). It was observed that TGFb was unable to increase
cAMP production in contrast to Forskolin treatment which
provided a significant increase in cAMP levels as expected. Next,
we examined IkB protein following TGFb treatment for specified
times to determine whether the activation of PKA by TGFb was
due to IkB degradation (Figure S3). The IkB levels remained
unchanged following TGFb treatment. Therefore, PKA is
activated by TGFb in a cAMP and IkB independent manner in
FET cells in agreement with the report from Zhang et al (2004).
To further confirm the functional significance of TGFb mediated
PKA activation, transcription factor CREB was tested, which has
been identified as a direct target of the cAMP-PKA signaling
pathway [15]. We observed that TGFb was able to stimulate the
phosphorylation of CREB (Figure 1E) with no change in the total
CREB levels (data not shown). Pretreatment of cells with H89
followed by TGFb exposure significantly reduced the phosphor-
ylation of CREB. Zhang et al (2004) emphasized the role of
activated Smad3 in TGFb mediated PKA activation. We
developed stable shRNA Smad3 knockdown in FET cells
(designated FET Smad3KD) (Figure S4). TGFb treatment on
these Smad3 knockdown cells was unable to activate PKA
(Figure 1F) indicating to the dependence of TGFb mediated
PKA activation on Smad3 as reported earlier [15].
TGFb/PKA signaling mediated XIAP downregulation
XIAP and survivin are well characterized IAP family members
recently documented as metastatic genes [5]. Their concerted role
in promoting cell survival and metastasis provides a strong
rationale for targeting the expression and/or activity of these
IAPs in advanced stages of cancer. An early event associated with
PKA activation is phosphorylation of survivin on Ser
20 in the
cytosol, but not in mitochondria [17]. This phosphorylation of
TGFb/PKA Transduceome Controls Cell Survival
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leading to XIAP degradation. Our data as well as earlier reports
indicate that the PKA activation response is an early event
following TGFb treatment and it attains maximal levels within 1 h
of TGFb treatment. We hypothesized that TGFb causes a
disengagement of aberrant cell survival by stimulating PKA
mediated disruption of the XIAP/survivin complex. FET cells
were treated with TGFb for the specified times followed by
determination of XIAP and survivin (Figure 2A and S5). TGFb
treatment downregulated both XIAP and survivin at the specified
times. As survivin phosphorylation has already been shown to be
linked to PKA activation, we focused our attention on the
regulation of XIAP. Degradation of XIAP was blocked by H89
pretreatment prior to TGFb exposure for the specified times
(Figure 2B). To examine the specificity of the response, we
compared the effect of TGFb on FET PKACata KD cells and
parental FET cells (Figure 2C). TGFb treatment had no effect on
XIAP protein levels in FET PKACata KD cells indicating the
dependence on the PKA catalytic subunit in TGFb mediated loss
of XIAP protein. To confirm the specificity of TGFb/PKA
pathway in this response, FET Smad3 KD cells were treated with
TGFb for the specified times and XIAP protein expression was
determined (Figure 2D). Consistent with the Smad3 dependence
of TGFb mediated PKA activation, stable shRNA knockdown of
Smad3 abrogated XIAP downregulation. A proteasomal inhibitor
(MG132) was used to determine whether loss of XIAP was
dependent upon proteasomal degradation (Figure 2E). It was
observed that pretreatment of FET cells with MG132 (15 mM) for
1 h prior to TGFb treatment completely abolished the XIAP
degradation indicating that XIAP is degraded within the
proteasome. PKA is an important regulator of proteasomal
activity and PKA has been shown to co-purify with the
proteasome [19,20]. We hypothesized that TGFb/PKA mediated
regulation of proteasomal activity may provide another layer of
control of IAP expression (beyond the PKA induced phosphor-
ylation of survivin on Ser
20). Earlier reports indicate that PKA
phosphorylates the Rpt6 ATPase, which unfolds and transports
substrates into the proteasome and this phosphorylation enhances
the chymotrypsin proteasomal activities of the proteasome [21].
To this end, we determined whether TGFb mediated PKA
activation is able to increase the chymotrypsin-like proteasomal
activity using a proteasomal activity assay. TGFb treatment of
Figure 1. TGFb activates PKA in colon cancer cells. FET cells treated with TGFb (5 ng/ml) activated PKA in a time (A) and concentration (B)
dependent manner. PKA inhibitor H89 (15 mM) was used to inhibit PKA activation. Forskolin (10 mM) was used as a positive control. Comparison of
parental FET and FET PKACata KD cells to TGFb mediated PKA activation (C). Knockdown of catalytic a-subunit abrogated PKA activation by TGFb.
PKA activation by TGFb is independent of cAMP generation as determined by cAMP assay (D). TGFb leads to CREB activation in FET cells (E). Actin was
used as loading control for western blots. PKA activation by TGFb is Smad3 dependent as determined by knockdown of Smad3 in FET cells (F). The
results are expressed as mean 6 S.E.M (n=3). All experiments have been repeated three times independently.
doi:10.1371/journal.pone.0019335.g001
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the proteasome within 1 h (Figure 2F). H89 pretreatment prior to
TGFb exposure completely abrogated the basal level of the
proteasomal chymotrypsin-like activity and completely abolished
the stimulatory effects of TGFb on the proteasome.
Collectively, these data lead to the hypothesis that the TGFb/
PKA signaling regulates XIAP expression at multiple levels with
activation of PKA leading to phosphorylation of key proteasomal
components that promote proteasomal degradation of XIAP.
AKAP regulates TGFb/PKA mediated XIAP
downregulation
There is an abundance of A-kinase anchoring proteins (AKAPs)
which compartmentalize the PKA and other enzymes to the
vicinity of specific cellular organelles for carrying out enzyme
function. We hypothesized that AKAPs are a critical component
in TGFb/PKA mediated XIAP downregulation. It is well
documented that the subcellular localization of PKA regulatory
subunits (PKARI and/or PKARII) is mediated through interac-
tions with AKAPs [22]. AKAP inhibitor Ht31, a synthetic thyroid
anchoring peptide has been shown to be a very potent competitive
inhibitor of PKARII/AKAP interaction, thereby preventing PKA
anchoring [23]. To ensure that the Ht31 was specifically targeting
AKAP-PKA interactions, we performed PKA activity assays on
FET cells to determine the extent of PKA activation following
pretreatment with Ht31 (25 mM) prior to TGFb exposure
(Figure 3A). In agreement with earlier studies [15], Ht31 was
able to block the TGFb mediated PKA activation. Since AKAP-
PKA interaction appears to be a requirement for TGFb mediated
PKA activation, we reasoned that these interactions might also be
required for downstream signaling events leading to XIAP loss
(Figure 3B). Addition of Ht31inhibitor for 1 h prior to TGFb
treatment for specified times completely abrogated the XIAP loss.
Since the AKAP family includes more than 50 members [24],
the challenge was to identify an individual AKAP that was
responding to the TGFb/PKA effects on XIAP. After initial
screening for the presence of different AKAP family members in
FET cells, we found AKAP149 protein expression in these colon
cancer cells. AKAP149 (also termed D-AKAP1 and AKAP121 in
mouse) has been identified as a membrane protein of the
mitochondria [25]. It has been reported that mitochondrial
AKAP121 is involved in targeting cAMP activated PKA to the
outer mitochondrial membrane (OMM) and plays a role in
mitochondrial biogenesis and survival [26]. We hypothesized
based on the understanding that the mitochondrial XIAP and
survivin move to the cytoplasm following a stress response that
AKAP149 might be regulating TGFb/PKA mediated XIAP
degradation. Expression of an AKAP149 small interfering RNA
(siRNA) prevented the TGFb mediated PKA activation
(Figure 3C–D). Further, we observed that TGFb was unable to
downregulate XIAP protein in AKAP149 siRNA knockdown cells
compared to parental FET control cells (Figure 3E). This pro-
Figure 2. TGFb/PKA signaling mediated XIAP downregulation. TGFb (5 ng/ml) treatment for indicated times downregulates XIAP in FET cells
(A) and this effect is mediated by PKA as pretreatment with PKA inhibitor H89 prior to TGFb exposure abrogates XIAP loss (B). Stable shRNA
knockdown of PKA catalytic subunit in FET cells leads to abrogation of XIAP loss (C). Stable shRNA knockdown of Smad3 leads to abrogation of XIAP
loss in FET cells (D). TGFb (5 ng/ml) mediated XIAP downregulation is a proteasomal event. Pretreatment with proteasomal inhibitor MG132 (15 mM)
abrogated XIAP loss by TGFb (E). TGFb mediated activation of PKA leads to activation of chymotrypsin activity within the proteasome and this effect
is abrogated by H89 (F). The results are expressed as mean 6 S.E.M (n=3). Actin was used as loading control for western blots. All experiments have
been repeated three times independently.
doi:10.1371/journal.pone.0019335.g002
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function of mitochondrial AKAP121 (or its human homologue
AKAP149) in promoting survival.
We next questioned whether the effect of AKAP149 was
selective in this TGFb/PKA effect. While AKAP-PKA interaction
is a global phenomenon, validation of AKAP149 as selectively
regulating TGFb/PKA signaling would be a novel extension of
our understanding of the TGFb/PKA mediated XIAP downreg-
ulation. AKAP220 has been shown to regulate protein phospha-
tase 1 (PP1) activity by coordinating the location of PKA and PP1
catalytic subunit [27]. We silenced the expression of AKAP220 in
FET cells with AKAP220 siRNA. These transfected cells when
treated with TGFb had no effect on either the induction of PKA
activity or XIAP downregulation (data not shown). Taken
together, AKAP scaffolding plays a pivotal role in the TGFb/
PKA pathway mediated XIAP downregulation with mitochondrial
localized AKAP149 being necessary for the TGFb/PKA mediated
response.
Involvement of PP2A in TGFb/PKA mediated XIAP
downregulation
It has been observed that activation of PKA leads to the
inactivation of AKT through dephosphorylation by protein
phosphatase 2A (PP2A) [28]. This led to the hypothesis that
TGFb mediated activation of PKA is responsible for the repression
of AKT activation that we previously reported as a consequence of
TGFb signaling [13]. Consequently, we determined PP2A activity
in FET cells (Figure 4A). TGFb treatment for specified times
significantly increased the PP2A activity. PP2A selective inhibitor
okadaic acid (OA, 50 nM) was able to completely abolish the
PP2A activation when treated alone or pretreated prior to TGFb
exposure. Next, we tested the role of TGFb in mediating AKT
inactivation and XIAP loss (Figure 4B). It was observed that TGFb
mediated dephosphorylation of AKT is PP2A dependent as
reflected by the ability of OA to block the TGFb mediated
dephosphorylation of AKT. XIAP downregulation was also
abolished by OA treatment. Although PP2A is a tumor suppressor
involved in the control of several cell survival pathways [29],
documentation of a role in subverting cell survival signaling within
the TGFb pathway is a novel extension of PP2A function.
To further validate the role of PP2A in TGFb/PKA signaling,
we generated stable shRNA PP2A catalytic subunit knockdown in
FET cells designated FET PP2A Cat KD (Figure 4C). TGFb
treatment of FET PP2A Cat KD cells showed PKA activation
indicating that PKA activation is upstream of PP2A activation
(Figure 4D). However, stable shRNA knockdown of the PP2A
catalytic subunit completely abolished TGFb mediated XIAP
inhibition and showed sustained phosphorylation of AKT as well
(Figure 4E). FET PKACata KD cells treated with TGFb also
showed a sustained phosphorylation of AKT (data not shown).
While inhibition of AKT activation would have potential for
many effects on cell survival, one effect that is of particular interest
as related to TGFb/PKA function is in the context that it targets
XIAP stability. A previous study reported that XIAP is
phosphorylated by AKT on Ser
87 which leads to increased
stabilization of XIAP and decreased apoptosis of ovarian cancer
cells in response to cisplatin [30]. We reasoned that PP2A
inhibition of AKT activity may represent an additional mechanism
for the disruption of the stabilization of XIAP that is targeted by
the TGFb/PKA pathway through enhancement of PP2A activity.
To this end, FET cells were treated with TGFb or pretreated with
different TGFb/PKA pathway inhibitors prior to TGFb exposure
Figure 3. AKAP regulates TGFb/PKA mediated XIAP downregulation. AKAP inhibitor Ht31 (25 mM) treatment for 1 h prior to TGFb exposure
abrogates TGFb mediated PKA activity (A) and TGFb mediated XIAP loss (B). AKAP149 siRNA knockdown was done on FET cells (C). Knockdown of
AKAP149 leads to abrogation of TGFb mediated PKA activity (D) and XIAP downregulation (E). The results are expressed as mean 6 S.E.M (n=3). Actin
was used as loading control for western blots. All experiments have been repeated three times independently.
doi:10.1371/journal.pone.0019335.g003
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immunoblotted for possible proteins bound to XIAP. We found
an association of XIAP with pAKT (Figure 4F). Following TGFb
treatment, there was a significant dissociation of the XIAP-pAKT
complex. However, pretreatment with H89 or Ht31 prior to
TGFb exposure completely abrogated XIAP-pAKT dissociation
of the two proteins indicating that TGFb/PKA signaling mediated
inactivation of AKT destabilizes XIAP leading to its proteasomal
degradation. Therefore, using inhibitor and stable knockdown
studies, we underscore the novel finding that TGFb/PKA
signaling mediates loss of XIAP protein by a PKA-PP2A
dependent repression of AKT activation leading to XIAP loss.
TGFb receptor reconstitution leads to decreased
metastatic colonization: Impact on TGFb/PKA signaling
We have developed technology for orthotopic colonic implan-
tation of human colon cancer lines in athymic mice that allows for
reproducible quantitative analysis of metastasis to the liver and
lungs [31,32,33]. The metastatic pattern displayed in this model
system reflects the nature of metastatic spread in human patients.
Highly metastatic GEO colon cancer cells were used to further
understand the impact of TGFb/PKA signaling on metastasis.
GEO cells have attenuated TGFbRI expression and thus
attenuated TGFb tumor suppressor signaling as well [8]. We
have utilized colonic orthotopic implantation of subcutaneously
grown xenografts to characterize factors that influence the extent
of metastasis to liver and lungs without affecting invasion at the
primary tumor site [31,33]. GEO cells were found to be highly
metastatic in this orthotopic model as reflected by metastatic
colonization in 53% of the implanted animals (Table 1). Rescue of
receptor attenuation in GEO cells by transfection of a TGFbRI
expression vector (designated GEORI) resulted in the reduction of
metastatic incidence to about 20% of animals implanted without
affecting invasion at the primary site as both GEO and GEORI
transfected animals gave rise to an invasive primary tumor in
100% of implanted animals. GEO transplanted animals developed
robust liver metastasis compared to GEORI (Figure 5A). Hema-
toxylin and Eosin (H&E) staining showing liver metastasis in GEO
cells is shown in Figure 5B. The characterization of GEO tumors
showed increased cell survival signaling as reflected by lower
TUNEL rates relative to GEORI tumors indicating a repression of
metastatic colonization by TGFb tumor suppressor signaling is
associated with repression of cell survival signaling in vivo
(Figure 5C–D). Further, no change in Ki67 IHC staining was
observed between highly metastatic GEO and poorly metastatic
GEORI primary tumors indicating no difference in proliferation
rate in vivo between GEO and GEORI tumors (Fig 5E–F). The in
vivo findings indicate that the restoration of TGFb receptor
suppresses metastatic competence in GEO cells at the level of
metastatic colonization as opposed to preventing invasion.
Figure 4. Involvement of PP2A in TGFb/PKA mediated XIAP downregulation. FET cells were treated with TGFb (5 ng/ml) for the indicated
time and PP2A activity was determined using PP2A activity assay protocol as described in materials and methods (A). PP2A inhibitor okadaic acid (OA,
50 nM) was used to inhibit PP2A. Pretreatment with OA prior to TGFb (5 ng/ml) treatment abrogated TGFb mediated XIAP loss and
dephosphorylation of AKT (B). Stable shRNA knockdown of PP2A catalytic a-subunit were done on FET cells (C). Knockdown of PP2A catalytic a-
subunit led to abrogation of TGFb (5 ng/ml) mediated XIAP downregulation without affecting PKA activity (D–E). XIAP immunoprecipitation studies
in FET cells treated with TGFb (5 ng/ml) or pretreated with H89 or Ht31 for 1 h prior to TGFb exposure. XIAP dissociates from pAKT following TGFb
treatment for indicated time (F). Inhibiting the PKA activity by H89 or AKAP-PKA interaction with Ht31 abrogates the TGFb mediated XIAP-pAKT
dissociation.
doi:10.1371/journal.pone.0019335.g004
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signaling is the elucidation of the molecular mechanism by which
metastasis is inhibited. Based on the decrease in metastatic
incidence with TGFb receptor reconstitution leading to rescue of
TGFb signaling, we hypothesized that TGFb/PKA mediated
XIAP downregulation requires an intact TGFb signaling mech-
anism which is lost in the highly metastatic GEO cells. However,
rescue of TGFb signaling by receptor reconstitution in GEORI
cells leading to decreased metastatic incidence should increase
TGFb/PKA signaling and its downstream effects on XIAP. GEO
cells with attenuated TGFb signaling had no PKA activation with
TGFb exposure (Figure 5G). However, GEORI cells with
functional TGFb signaling due to receptor reconstitution had a
robust increase in PKA activation by TGFb which was about 4-
fold higher than the control. A second colon carcinoma cell line
(CBS cells) with attenuated TGFbRII signaling [34] also showed
reduced metastasis after rescue of receptor deficiency (data not
shown). A similar response in PKA activity was observed in highly
metastatic CBS cells compared to the poorly metastatic CBSRII
cells after TGFb treatment in vitro (Figure 5H).
Following this observation, we hypothesized that the highly
metastatic GEO and CBS cells would be resistant to the TGFb/
PKA signaling mediated loss of XIAP protein. We reasoned that
the inability of TGFb signaling to induce PKA activation in these
cells due to receptor inactivation would also prevent its
downstream effects on XIAP thereby making these cells more
metastatic through increased pro-survival signaling. While GEO
Table 1. Results of orthotopic implantation demonstrating
the primary invasion and metastases based on histologic
evaluation.
Cell Line Primary Liver Mets Lung Mets Liver or Lung Mets
GEO 38/38 (100%) 17/38 (45%) 8/38 (21%) 20/38 (53%)
GEOR1 30/30 (100%) 6/30 (20%) 0/30 (0%) 6/30 (20%)
doi:10.1371/journal.pone.0019335.t001
Figure 5. TGFb receptor reconstitution leads to decreased metastatic colonization: Impact on TGFb/PKA signaling. Comparison of GFP
images of metastatic progression into liver in GEO and GEORI mice (A). GEO Colon Cancer Liver H&E staining showing liver metastasis (B). Comparison
of primary tumor sections of GEO and GEORI mice by TUNEL assay staining as mentioned in Materials and Methods to determine their apoptotic rates
(C). The apoptotic rates were quantified (D). Comparison of primary tumor sections of GEO and GEORI mice by Ki-67 staining as mentioned in
Materials and Methods to determine their rates of proliferation (E). The proliferation rates were quantified (F). TGFb receptor reconstitution leads to a
change in PKA activity. Comparison of PKA activity in highly metastatic GEO cells vs. poorly metastatic GEORI cells (G) and in highly metastatic CBS
cells vs. poorly metastatic CBSRII cells (H). Comparison of TGFb (5 ng/ml) exposure between GEO and GEORI cells (I) and CBS and CBSRII cells (J). PKA
inhibitor H89 abrogated TGFb mediated XIAP loss in GEORI and CBSRII cells (K).
doi:10.1371/journal.pone.0019335.g005
TGFb/PKA Transduceome Controls Cell Survival
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19335and CBS both showed no response to TGFb treatment at specified
times (Figure 5I–J), GEORI and CBSRII cells showed XIAP
downregulation for similar treatments (Figure 5I–J). To validate
the role of PKA activation in XIAP downregulation by TGFb,w e
used H89 pretreatment prior to TGFb exposure in GEORI and
CBSRII cells (Figure 5K). In line with our observations in FET
cells, both GEORI and CBSRII cells pretreated with H89 showed
abrogation of TGFb/PKA mediated XIAP downregulation. Thus,
TGFb receptor restoration in deficient cells was able to reactivate
the TGFb/PKA signaling pathway in poorly metastatic cells
leading to XIAP loss. These cells mimicked the observation from
FET cells, which has a functional TGFb/PKA signaling.
Therefore, the in vitro results are consistent with the in vivo
observation that TGFb receptor rescue reactivates the attenuated
TGFb signaling in controlling cell survival and metastasis. Taken
together, these findings along with clinical evidence of TGFb
receptor silencing suggests that reconstitution of TGFb receptor
expression could lead to inhibition of growth and/or induce
apoptosis in highly progressed metastatic colon cancer cells by the
TGFb/PKA signaling pathway.
TGFb/PKA signaling controls cell survival
Recently, we showed that TGFb signaling leads to cell death in
FET cells in vitro in response to stress [13]. Based on this
background and the current findings regarding AKAP-PKA
transduceome signaling in XIAP downregulation, we hypothesized
that the tumor suppressor effects of TGFb can be mediated
through the TGFb/PKA signaling axis. Using FET cells as an
established model, we tested the effects of TGFb treatment on cell
death to further understand the role of the TGFb/PKA signaling
pathway in abrogating cell survival. TGFb treatment for 48 h
showed approximately 2-fold increase in cell death (Figure 6A). To
better understand the impact of PKA in the TGFb effect, cells
were pretreated with low dose of H89 (1 mM) prior to TGFb
treatment. Compared to control FET cells, inhibiting the PKA
activation with H89 significantly decreased the cell death in these
cells. To further confirm the role of PKA, FET PKACata KD cells
were treated with TGFb for the specified times and cell death was
assessed in comparison to FET cells (Figure 6B). PKA catalytic
subunit knockdown completely abrogated the cell death by TGFb
treatment indicating that PKA activation is critical in TGFb
mediated cell death.
Since AKAP149 was observed to be a critical player in the
TGFb/PKA mediated XIAP loss, we reasoned that AKAP149
might also be critical for the TGFb/PKA mediated cell death.
Silencing of AKAP149 expression using AKAP149 siRNA in FET
cells followed by TGFb treatment to assess cell death was
performed (Figure 6B). AKAP149 knockdown completely abro-
gated cell death in these cells. The siRNA knockdown studies
indicate that AKAP149 is selective for TGFb/PKA signaling in
FET cells.
Since TGFb mediated PKA activation leads to activation of
PP2A followed by AKT dephosphorylation and XIAP downreg-
ulation, we reasoned that inhibiting PP2A should also alter the cell
death response to TGFb. For this reason, FET PP2A Cat KD cells
were compared with parental FET cells for effects on cell death by
TGFb signaling (Figure 6B). Indeed, stable knockdown of PP2A
catalytic subunit completely abrogated the PP2A mediated cell
death.
GEO cells reconstituted with TGFbRI showed a decrease in
metastatic capability. Consequently, we determined whether
receptor reconstitution also causes an increase in functional TGFb
tumor suppressor signaling leading to increased cell death in these
cells. Comparison of GEO and GEORI cells with respect to cell
death by TGFb treatment for 48 h was performed (Figure 6C) and
similarly, comparisons were performed with CBS and CBSRII
cells as well (Figure 6D). Death assays revealed a striking difference
in their responsiveness to TGFb induced cell death. While the
GEO and CBS cells were completely resistant to TGFb mediated
cell death; the GEORI and CBSRII cells showed significant
increases in cell death following TGFb treatment. We hypothe-
sized that the increase in cell death due to receptor reconstitution
was due to the restoration of TGFb/PKA signaling. To this end,
GEORI and CBSRII cells were treated with TGFb or pretreated
with H89 prior to TGFb exposure and cell death was assessed
(Figure 6E–F). In both GEORI and CBSRII cells, H89 was able to
abrogate the TGFb response indicating the importance of TGFb/
PKA signaling in controlling cell survival in these cells.
We hypothesized that the TGFb/PKA mediated XIAP
downregulation would require dissociation of the XIAP and
survivin complex prior to XIAP degradation. We compared the
endogenous levels of the XIAP/survivin complex in CBS and
CBSRII cells and determined whether TGFb was able to
dissociate the XIAP/survivin complex in a PKA dependent
manner (Figure 6G). CBS cells (TGFb signaling deficient) had
higher levels of survivin bound to XIAP compared to CBSRII
cells with restored TGFb signaling. Treatment of TGFb
completely dissociated survivin from XIAP in CBSRII cells while
survivin remained bound to XIAP in CBS cells. Blocking PKA
activation by H89 significantly abrogated the TGFb mediated
XIAP/survivin complex dissociation in accordance with the well
documented role of PKA in dissociation of the XIAP/survivin
complex [17]. Most XIAP/survivin complex studies have been
performed using overexpression approaches as only a small
fraction of the total cellular XIAP and survivin form a complex.
We used the endogenous protein as opposed to the other
approach since overexpression might lead to artifacts in the
interaction. Therefore, TGFb was able to dissociate XIAP/
survivin complex through the TGFb/PKA signaling in poorly
metastatic cells which have a restored TGFb signaling as opposed
to their highly metastatic counterparts deficient in functional
TGFb signaling.
Discussion
TGFb signaling and aberrant cell survival
We have identified a novel mechanism of TGFb tumor
suppressor signaling pathway that is capable of counteracting
aberrant cell survival. This TGFb/PKA/AKAP149 dependent
transduceome involves a TGFb initiated series of kinase and
phosphatase events that sequentially converge on the inhibition of
XIAP function in promoting cell survival and thereby permitting
cell death in response to stress. The proposed mechanism involves
the activation of PKA in a manner that is independent of cAMP,
but AKAP and Smad3 dependent. PKA activation results in PP2A
mediated dephosphorylation of pAKT followed by destabilization
of XIAP resulting in its proteasomal degradation (Figure 7). The
ability of XIAP to directly inhibit caspases in vivo [35] makes it a
critical element in the control of apoptotic threshold in cancer
cells. More recently, PKA was found to mediate compartmental-
ized regulation of survivin on Ser
20 selectively in the cytosol but
not in mitochondria leading to the control of survival signals
through degradation of the IAPs [17]. A critical aspect of this
novel TGFb/PKA pathway is the implication that the TGFb
mediated activation of an AKAP/PKA complex initiates a multi-
functional cascade directed at disruption of XIAP mediated cell
survival involving several different targets including PP2A and the
proteasome along with cytosolic survivin.
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PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19335The tetrameric PKA holoenzyme is a Ser/Thr kinase consisting
of two catalytic (C) subunits bound to two (R) subunits (RIa/b and
RIIa/b) that renders it inactive [16]. Classically, following
elevation of cAMP, the C-subunits disengage from the R-subunits
and actively phosphorylate proteins in the cellular vicinity [27].
The correct sub-cellular localization of the PKA holoenzyme
within cellular compartments is a function of scaffolding and
anchoring proteins AKAPs [27] which contribute to the spatio-
temporal regulation of second messenger signaling events [24].
Similar to Zhang et al (2004), we found that AKAP-PKA
interaction was required for PKA activation by TGFb. Earlier
work has suggested that AKAPs are required for subcellular
localization of PKA and interaction with Smads [15]. We
identified a specific mitochondrial localized AKAP149, as having
a critical role in TGFb mediated PKA activation. Knockdown of
AKAP149 abrogated TGFb induced PKA activation and
downstream signaling leading to XIAP loss. We demonstrated
for the first time that AKAP149/PKA was directly involved in the
TGFb’s ability to induce cell death in colon cancer cells. Our study
demonstrates that AKAP149 might have context dependent effects
based on the mechanism of PKA activation. The cAMP mediated
AKAP121/PKA signaling to mitochondria inhibits apoptosis [26].
However, we have demonstrated here that AKAP149 is also
involved in a pro-apoptotic role during TGFb mediated PKA
activation independent of cAMP as evidenced by AKAP149
siRNA studies.
An intriguing observation made in our studies which originally
showed that TGFb signaling inhibits survivin expression was that
TGFb signaling also mediated inactivation of AKT [13]. The
activation of PKA has been shown to inactivate AKT through
dephosphorylation by PP2A [28]. Consequently we tested the
hypothesis that inactivation of AKT is dependent upon PP2A in
our studies of TGFb/PKA mediated control of XIAP expression.
PP2A is ubiquitously expressed as a trimeric complex composed by
a C-catalytic subunit, an A-scaffolding subunit and a B-targeting
subunit which is drawn from among several families of multiple
isoforms [36] . PP2A has been observed to have a tumor
suppressor function [29] playing a critical role in apoptotic cell
Figure 6. TGFb/PKA signaling controls cell survival. TGFb induces cell death in FET cells mediated by the PKA as determined by DNA
fragmentation assay (A). Pretreatment with PKA inhibitor H89 (1 mM) for 1 h prior to addition of TGFb (5 ng/ml) in the same media for indicated time
abrogated the TGFb mediated cell death. Comparison of cell death by DNA fragmentation assays between parental FET and FET PKACata, FET
AKAP149 and FET PP2A Cata KD cells in response to TGFb (5 ng/ml) exposure for indicated time (B). Differential levels of cell death induced by TGFb
(5 ng/ml) exposure for indicated time in between GEO/GEORI cells (C) and CBS/CBSRII cells (D). TGFb induces cell death in GEORI (E) and CBSRII (F)
cells mediated by the PKA as determined by DNA fragmentation assay. Pretreatment with PKA inhibitor H89 (1 mM) for 1 h prior to addition of TGFb
(5 ng/ml) in the same media for indicated time abrogated the TGFb mediated cell death. TGFb mediates dissociation of XIAP-survivin complex in
poorly metastatic CBSRII cells compared to highly metastatic CBS cells in a PKA dependent manner (G).
doi:10.1371/journal.pone.0019335.g006
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TGFb has been shown to induce G1 arrest mediated through
PP2A [37]. Studies with the PP2A selective inhibitor okadaic acid
(OA) have shown that it acts as a tumor promoter in mouse skin
carcinoma [38]. We demonstrated that TGFb mediated activation
of PKA was upstream of PP2A activation by stable transfection of
FET cells with PP2A catalytic shRNA or treatment with OA
resulting in PP2A mediated XIAP degradation through inactiva-
tion of AKT. Although PP2A is a tumor suppressor involved in the
control of several cell survival pathways, documentation of a role
in subverting cell survival signaling within TGFb function is a
novel extension of its function.
We have shown that XIAP is associated with pAKT and this
association is disrupted following TGFb treatment (Figure 4F).
AKT along with some of its substrates constitute a major cell
survival pathway [30]. Importantly, the anti-apoptotic functions of
AKT have been proposed to be at the post-mitochondrial level. It
has been shown to directly phosphorylate and inactivate caspase 9
and Bax [30]. XIAP inhibits death-signaling pathways also at the
post-mitochondrial level [30] and has been documented as a
physiological substrate of AKT. In HEK293 cells, AKT physically
associates with XIAP and phosphorylates XIAP on Ser
87, thereby
stabilizing XIAP and preventing it from auto-ubiquitination [30].
We have now demonstrated that pAKT and XIAP are in a
complex and TGFb is able to modulate the complex formation.
Further, we observe that dissociation of complex formation by
TGFb was inhibited by H89 and Ht31. This strongly supports the
notion that TGFb exerts its effects on cell survival through the
TGFb/PKA transduceome signaling.
In association with direct regulation of XIAP by TGFb/PKA
signaling, we also demonstrated that chymotrypsin-like activity of
the proteasome is induced by TGFb in a PKA dependent manner.
XIAP can be auto-ubiquitinated and degraded when treated with
DNA damaging agents like chemotherapeutic drugs [30]. The fact
that XIAP has an E3-ligase which could act as a scaffold for EI or
E2 ubiquitination enzymes is consistent with XIAP as a potential
proteasomal target. PKA is an important kinase in proteasome
phosphorylation and the regulation of metabolic function [20].
Collectively, these data lead to the indicate that the TGFb/PKA
transduceome regulates XIAP and survivin expression at multiple
levels with activation of PKA complex leading to phosphorylation
of key proteasomal components such as Rpt6 [21] which might
contribute to the ubiquitin-proteasome mediated degradation of
XIAP as well as other related cell survival mediators.
TGFb receptor reconstitution suppresses metastasis
We have made the novel observation that reconstitution of
TGFb receptor TGFbRI in highly metastatic GEO colon cancer
Figure 7. Schematic representation of TGFb/PKA transduceome signaling.
doi:10.1371/journal.pone.0019335.g007
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from orthotopic xenografts. This observation raises the therapeutic
possibility that TGFb can suppress metastatic competence after
this advanced state of progression is attained in cells with
attenuated type I and/or II TGFb receptor expression (designated
TGFbRI or TGFbRII).
We have made the novel observation that rescue of attenuated
receptor expression does inhibit metastatic capability in GEORI
(reconstituted with RI) transplanted orthotopic models in vivo even
though invasion at the primary tumorsite wasmaintained (Table 1).
This finding indicates that the effect of receptor reconstitution was
on the ability to form progressively growing colonies at the distal site
rather than preventing escape from the primary tumor. This result
alsosuggestedthat theinhibitionofdistant organcolonizationmight
be related to stress induced cell death associated with regenerated
TGFb signaling in response to the foreign micro-environment for
growth of the colon cancer cells in the liver and lungs. These results
are significant because they raise the possibility that regeneration of
attenuated TGFb signaling leading to activation of the TGFb/PKA
transduceome would be an effective strategy to target the treatment
of metastasis. As discussed in the introduction, epigenetic loss of
TGFb receptors is a frequent occurrence in a broad array of
different types of cancer. Thus, there is the potential for translating
our novel observations into the clinic. To this end, we found that
pancreatic, breast and colon cancer cell lines frequently exhibited
loss of TGFbRII and/or RII due to transcriptional repression. We
identified HDAC inhibition as mechanism for rescue of TGFb
receptor expression in these histological types of cancer
[39,40,41,42,43,44].
Studies on different cancer types provide extensive support for
loss of TGFb receptor expression as an important contributor to
tumor progression in subgroups of several types of cancer [11,12].
However, there is also evidence from additional clinical studies
indicating that other subgroups exist within the same histopath-
ological types of cancer that utilize corrupted TGFb signaling via
TGFbRI and TGFbRII as a means of contributing to cancer
progression [45]. Thus, various subgroups of breast and colon
cancer have evolved different strategies for generating malignant
progression. The existence of corruption of TGFb signaling as a
mechanism for malignant progression does not preclude the
clinical importance of loss of TGFb tumor suppressor signaling
due to deficiency of receptor expression as a potential target for
cancer therapy. In fact, the evidence for the importance of
receptor loss in clinical cancer is, as indicated above, significantly
more developed than the evidence for corrupted TGFb signaling
which is largely restricted to in vitro investigations at this point.
In an effort to determine the relationship between the TGFb/
PKA transduceome and the capability of a tumor for metastatic
spread, we investigated the molecular aspects of the TGFb/PKA
transduceome signaling in the context of metastatic progression in
highly metastatic GEO and CBS cells and their poorly metastatic
counterpart GEORI and CBSRII where receptor reconstitution
has led to a decrease in metastatic spread. Since metastatic
deposits, like primary cancers, are faced with hypoxic stress and
must face the additional challenge of growth in a foreign
microenvironment, it seems likely that even established metastases
must retain their aberrant survival characteristics.
Striking difference in TGFb/PKA signaling activity and
downstream signaling leading to XIAP downregulation was
observed when highly metastatic (GEO, CBS) and their poorly
metastatic colon cancer counterparts (GEORI and CBSRII) were
compared. Therefore, reconstitution of TGFb receptors in
metastatic models with attenuated TGFb signaling leading to
metastasis might also reconstitute TGFb/PKA signaling in
established metastases which could affect their survival. These
lines of evidence lead to the consideration that the TGFb/PKA
transduceome is a critical component in steady-state suppression of
abnormal survival signaling that prevents formation of metastases
by disrupting the XIAP/survivin cell survival pathway.
In conclusion, understanding drivers for metastasis in human
cancer is important for potential development of therapies to treat
metastases (most prominent cause of death from solid cancers).
The role of loss of tumor suppressor activities in the metastatic
process is essentially unknown. Presently, loss of TGFb signaling is
largely regarded as a driver for transition from a benign to a
malignant state subsequently leading to metastatic spread by other
mechanisms or even by usurping aspects of TGFb signaling for
oncogenic mechanisms such as the acquisition of EMT. However,
we have now shown that loss of TGFb tumor suppressor signaling
is a driver for metastatic colonization of distant organs from the
primary tumor. Importantly, loss of TGFb signaling does not
affect invasion as reflected by retention of a 100% rate of invasion
at the primary site of metastatic cells in which TGFb signaling has
been rescued and metastatic potential inhibited. This indicates
that while loss of TGFb signaling enables the transition from a
benign to a malignant state its loss does not drive the earliest step
of the metastatic process.
However, we have shown here that loss of TGFb signaling is
necessary to allow the last step of the metastatic process-
colonization of the metastatic site. Moreover, we have identified
a novel TGFb tumor suppressor pathway that acts directly on a
known cell survival mechanism that responds to stress with the
survivin/XIAP dependent inhibition of caspases that effect
apoptosis. This survival mechanism is apparently not necessary
for malignant behavior at the primary site once the cancer cells
have made the transition from the benign state since its inhibition
by restoration of TGFb tumor suppressor signaling does not alter
malignant behavior at the primary site.
Our work indicates the potential for developing anti-metastasis
therapy based on inhibition of this very important aberrant cell
survival mechanism by this novel, multifaceted TGFb induced
pathway. Our previous body of work showing that HDACi’s act at
least in part through the rescue of TGFb receptor I and II
expression and TGFb tumor suppressor activity in a wide variety
of cancer cells indicates the clinical potential of this concept.
Since TGFb signaling responses can be supportive of events that
support malignant progression such as EMT and suppression of
TGFb signaling as a therapy for cancer has been supported by
experimental evidence, therapeutic strategies for the inhibition of
TGFb signaling in cancer therapy are currently being pursued.
However, our work indicates that the relationship between TGFb
signaling and tumor suppressor function may be governed by
context even in the later stages of cancer. The concept that the
disruption of the balance between TGFb tumor suppressor activity
and the survivin/XIAP cell stress response enables metastatic
colonization of distant organs raises the concern that therapies
aimed at inhibition of TGFb signaling may be deleterious to at
least a subset of cancer patients. For example, it has been shown in
several types of cancer that progressive epigenetic silencing of
TGFb receptor I and/or II correlates with malignant progression.
Pharmacological inhibition of TGFb receptor signaling may
promote metastases in these patients.
Materials and Methods
All experiments involving animals were approved by the
University of Nebraska Medical Center Institutional Animal Care
and Use Committee (IACUC #: 07-047-08-FC).
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The FET [13] , GEO [8] and CBS [34] colon carcinoma cells
are routinely maintained in a serum free (SF) medium containing
insulin (20 ug/ml, Sigma) transferrin (4 ug/ml, Sigma) and EGF
(5 ng/ml; R&D Systems) as previously described [46]. Cells were
harvested after the addition of TGFb (5 ng/ml) at the specified
times. The TGFbRII, AKAP149, AKAP220 and PKA and PP2A
catalytic subunit antibodies were obtained from Santa Cruz
Biotechnology. The XIAP antibody was obtained from Abcam
and actin from Sigma. The survivin, TGFbRI, AKT, Smad3,
pSmad3, CREB, and IkBa antibodies as well as the PKA inhibitor
H89 were obtained from Cell Signaling Technology. The AKAP
inhibitor Ht31 and the phosphatase inhibitor Okadaic acid were
obtained from Calbiochem.
Western Blotting and Immunoprecipitation
Cells were lysed in a Tris-HCl based buffer containing 0.5%
NP-40 and appropriate protease and phosphate inhibitors as
described previously [13]. Protein concentration was determined
by bicinhoninic acid assay (Pierce). Immunoprecipitation was
performed with 500 ug protein aliquots using magnetic beads
(Millipore) according to manufacturer’s instructions.
RNA Interference Studies
Smad 3 (sc-38376-SH), PKA Catalytic a (sc-36240-SH) and
PP2A Catalytic a (sc-43509-SH) shRNA was obtained from Santa
Cruz. These vectors were co-transfected by electroporation as
described previously [34] with a puromycin selection vector and
FET clones were selected in SF medium containing 4 ug/ml
puromycin and 0.2% FBS. AKAP149 (sc-40301) and AKAP220
(sc-105049) siRNA and Transfection Reagent was obtained from
Santa Cruz and knockdown was performed according to the
manufacturer’s protocol.
PKA Activity Assay
PKA activity was measured using the PepTag non-radioactive
protein kinase assay (Promega) using kemptide (LRRASLG)
following the manufacturer’s protocol. For quantitative determi-
nation of cellular cAMP, the non-radioactive Direct Cyclic AMP
Enzyme Immunoassay kit (Assay Design) was used.
cAMP Assay
For quantitative determination of cAMP, non-radioactive
Direct Cyclic AMP Enzyme Immunoassay kit (Assay Design)
was utilized. Manufacturer’s protocol was followed for the assay.
PP2A Assay
Protein Phosphatase 2A (PP2A) activity was measured using the
non-radioactive PP2A immunoprecipitation assay (Millipore).
Proteasomal Activity Assay
The fluorometric Proteasome substrate III for chymotrypsin
(SUC-LLVY-AMC) and Peptidyl-glutamyl peptide hydrolyzing
(PGPH)-caspase-like activity proteasome substrate II (Z-LLG-
AMC) and the corresponding inhibitors were obtained from
Calbiochem. FET cells were plated at 800,000 cells/100 mm dish
inSFmedia.Onday5,cellsweretreatedwith TGFb(5 ng/ml)with
or without H89 (15 mM) pretreatment for 1 h and harvested in
proteasomal assay buffer [50 mM HEPES (pH 7.5), 5 mM EDTA,
150 mM NaCl and 1% Triton X-100 containing 2 mM ATP].
After quantification of protein concentration, cell lysates were
pretreated with 25 uM of the chymotrypsin-like activity inhibitor
Benzyloxy carbonyl Leu Leu phenylalaninal Inhibitor (ZLLF-
CHO) or the PGPH activity inhibitor Z-Gly-Pro-Phe-Leu-CH (Z-
GPFL-CHO) followed by incubation with chymotrypsin or PGPH
substrate for 1 h at 37uC as described by [47]. The chymotrypsin
and PGPH activities were measured fluorometrically.
Cell Death Assays
Apoptosis was measured by the Cell Death Detection ELISA Plus
kit (Roche) as described previously [13]. Inhibition of cell proliferation
was assessed by the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) assay as described previously [48].
Orthotopic Implantation for In Vivo Metastasis
All experiments involving animals were approved by the
University of Nebraska Medical Center Institutional Animal Care
and Use Committee. The orthotopic implantation methodology
has been described in details in the following publications from
Brattain laboratory [31,32,33]. Briefly, the GEO and GEORI cells
used in orthotopic assays were transfected with Green Fluores-
cence Protein (GFP). Exponentially growing GFP-labeled cells
were inoculated subcutaneously onto the dorsal surfaces of
separate BALB/c nude male mice. Once xenografts were
established (,1 week), they were excised and minced into
1m m
3 pieces. These pieces were then orthotopically implanted
into other BALB/c nude mice. For operative procedures, animals
were anesthetized with isofluorane inhalation. A 1 cm laparotomy
was performed and both the cecum and ascending colon were
exteriorized. Using 76 magnification and microsurgical tech-
niques, the serosa was disrupted by scraping in two locations. The
1m m
3 pieces of xenograft were sub-serosally implanted using an
8-0 nylon suture at the two points of serosal disruption. The bowel
was then returned to the peritoneal cavity and the abdomen was
closed with 5-0 vicryl suture. Subsequently, animals were
anesthetized with a 1:1 mixture of ketamine (10 mg/ml) and
xylazine (1 mg/ml) by intraperitoneal injection (0.01 ml/mg) and
weekly GFP fluorescence imaging was performed for up to 5
weeksWeekly GFP fluorescence imaging was performed for up to 5
weeks. Excitation of GFP in the light box facilitated identification
of primary and metastatic disease by direct near-real time
visualization of fluorescence in live animals. Both GEO and
GEORI cells gave rise to an invasive primary tumor in 100% of
the animals implanted.
Hematoxylin and Eosin, TUNEL and Ki67 Staining
Approximately 50 d post-implantation, the animals were
euthanized following proper IACUC protocol. The colon (with
primary tumor), liver, lungs, and heart were harvested. Following
the harvesting, organs were explanted, imaged, and immediately
placed in 10% neutral buffered formalin fixative for 24 h. This
was followed by tissues processing and embedding in paraffin.
Slides were then cut for hematoxylin and eosin (H and E) and
immunohistochemical characterizations. Serial sections were cut
to complement the H and E sections and were stained with an
IgG1 rabbit polyclonal antibody for Ki-67 (Dako North America,
Inc., Carpinteria, CA). Slides from paraffin embedded tissue
blocks were stained according to the Apotag (Oncor, Gaithers-
burg, MD) terminal nucleotidyl transferase-mediated nick end
labeling (TUNEL) assay kit. Detailed methodology and quantita-
tive analysis for these individual experiments has been described in
details in the [32,33,49].
Supporting Information
Figure S1 Activation of pSmad2.
(TIF)
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cells.
(TIF)
Figure S3 No change in IkB-a with TGFb treatment.
(TIF)
Figure S4 Smad3 shRNA knockdown in FET cells.
(TIF)
Figure S5 TGFb treatment downregulates survivin. Blocking
the proteasome with MG132 abrogates the TGFb mediated
survivin loss.
(TIF)
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